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A bstract Autosomal recessive spastic ataxia o f Charlevoix- 
Saguenay (ARSACS: MIM 270550) is a neurodegenerative 
disorder characterized by early-onset cerebellar ataxia with 
spasticity and peripheral neuropathy. This disorder, consid­
ered to be rare, was first described in the late seventies among 
French Canadians in the isolated Charlevoix-Saguenay region 
o f Quebec. Nowadays, it is known that the disorder is not only 
limited to this region but occurs worldwide. Our objective was 
to identify cases o f autosomal recessive spastic ataxia of 
Charlevoix-Saguenay (ARSACS) in Dutch patients with 
recessive early-onset cerebellar ataxia by sequencing the 
complete SACS gene. In a Dutch cohort of 43 index patients
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with ataxia onset before age 25, we identified 16 index 
patients (total 23 patients) with mutations in the SACS gene. 
Nine o f them had homozygous mutations, and seven o f them 
had compound heterozygous mutations. Retrospectively, the 
phenotype of patients carrying mutations was remarkably 
uniform: cerebellar ataxia with onset before age 13 years, 
lower limb spasticity and sensorimotor axonal neuropathy, and 
cerebellar (vermis) atrophy on magnetic resonance imaging, 
consistent with the core ARSACS phenotype previously 
described. The high rate of mutations (37%) identified in this 
cohort of Dutch patients suggests that ARSACS is substantially 
more frequent than previously estimated. We predict that the 
availability of SACS mutation analysis as well as an increasing 
awareness of the characteristic ARSACS phenotype will lead 
to the diagnosis o f many additional patients, possibly even at 
a younger age.
Keywords Early onset spastic cerebellar ataxia ■
Dutch population. Novel SACS gene mutations . ARSACS
Introduction
Autosomal recessive spinocerebellar ataxias constitute a 
heterogeneous group o f neurodegenerative disorders char­
acterized by ataxia mostly due to progressive degeneration 
o f the cerebellum, spinal cord tracts, and associated 
structures. The clinical phenotype of these disorders is 
broad and quite variable. A number o f recent reviews 
presented clinical diagnostic strategies to differentiate 
between the various types o f recessive cerebellar ataxias 
[1- 3]. Van de Warrenburg et al. grouped them into 
recognizable and more or less specific phenotypes: (a) 
ataxia with neuro(no)pathy, (b) spastic ataxia, (c) ataxia
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with oculomotor apraxia, and (d) Ramsay Hunt syndrome. 
The most common form, and representative o f the first 
group, is Friedreich’s ataxia (FRDA). Autosomal recessive 
spastic ataxia o f Charlevoix-Saguenay (MIM 270550), 
ARSACS, is a distinct form o f hereditary early-onset 
spastic ataxia. The disease was first described in the 
Charlevoix-Saguenay region o f Northeastern Québec in 
Canada [4]. Two founder mutations were identified in this 
population [5]. Shortly after mutation analysis became 
available, patients outside Québec were molecularly char­
acterized. To date, apart from the two Québec mutations, 27 
different additional mutations have been found in ARSACS 
patients outside Quebec, namely from Turkey, Tunisia, 
Italy, Spain, Japan, and recently from Belgium [6- 20]. The 
SACS gene is located on chromosome 13q12.12 and 
encodes the large protein sacsin [5]. Different transcripts 
o f the gene have been identified, and in total, 11 different 
exons within the gene have been described. The large 
transcript NM_014363.4 reported recently (www.ncbi.nlm. 
nih.gov) comprises nine coding exons consisting o f 13,737 
base pairs which encode 4,579 amino acids [6]. The large 
size o f the total coding sequence o f the SACS gene has 
precluded sequencing efforts for routine diagnostic use. 
The function o f  the sacsin protein is not yet known, but 
the protein may be involved in chaperone-mediated 
protein folding, as it contains a DnaJ domain and has 
some sequence similarity with the N terminus o f the heat 
shock protein 90 (Hsp90) [5]. As ARSACS is now known 
to occur worldwide, we initiated a systematic mutation 
analysis by direct automated sequencing o f the SACS 
exons and flanking intronic sequences in Dutch patients 
with an early-onset cerebellar ataxia presenting before the 
age o f  25, with the aim o f identifying additional mutations 
and determining the relative frequency o f  ARSACS 
among the autosomal recessive cerebellar ataxias in the 
Dutch population.
Materials and methods
Patient selection
To determine the frequency o f ARSACS among patients 
with early-onset cerebellar ataxia, we included in this study 
patients who presented with an early-onset cerebellar ataxia 
before the age o f 25 and for whom Friedreich’s ataxia was 
excluded through DNA mutation analysis. According to the 
clinical information which was either given on the DNA 
mutation analysis request form or gathered from medical 
records, 43 index patients fulfilled this criterion. Patients 
were recruited either through our own neurogenetics out­
patient clinic (n=26) as well as through referring neurolo­
gists and clinical geneticists from other hospitals (n =17).
Forty-one are native Dutch patients, one patient is o f 
English descent, and one is o f Turkish descent.
Molecular analysis
Molecular analysis was performed in 43 index patients. 
Genomic DNA was extracted from blood lymphocytes 
using standard procedures. We performed sequence analysis 
o f the transcript o f the SACS gene (NM_014363.4) 
mentioned in the NCBI database (www.ncbi.nlm.nih.gov) 
that comprises nine exons. The nine coding exons, 
including the gigantic exon described previously [5], as 
well as flanking intronic sequences of the SACS gene 
[G enB ank re fe ren ce  sequence  access io n  num ber 
NM_014363.4 (NCBI)] were polymerase chain reaction 
(PCR)-amplified from genomic DNA by using 45 primer 
pairs. The A o f the ATG start codon in exon 1 is defined as 
“position 1” for the numbering of nucleotides in mutation 
and DNA-variant nomenclature. Primer sequences and 
amplification parameters are available on request. Purified 
PCR products (using Multiscreen PCR^96 filter plate, 
Millipore Carrigtwohill, Cork, Ireland) were directly se­
quenced on an ABI 3730 automated sequencer (Applied 
Biosystems, Foster City, CA, USA). In addition, mutation 
analysis was performed in affected siblings or relatives of 
patients with one homozygous or two compound heterozy­
gous mutations in the SACS gene. If available, parental 
DNA was analyzed to confirm the location o f the mutation 
(s) in different SACS alleles. In all patients in whom no 
mutations in the nine coding exons o f the NM_014363.4 
transcript o f the SACS gene could be identified, we 
performed molecular analysis o f the additional two exons 
within the other transcripts.
Clinical assessment
A systemic and comprehensive clinical examination by a 
neurologist, a cardiologist, and an ophthalmologist was 
performed in 16 identified patients, with mutations in the 
SACS gene, o f families 1 through 4, 6, 7, 8 through 11, and 
13 (Tables 1 and 2) after having obtained informed written 
consent. For our clinical assessments, we used the Scale for 
the Assessment and Rating o f Ataxia (SARA), an eight- 
item scale that provides a comprehensive rating o f simple 
ataxia tests: (item 1) gait, (item 2) stance, (item 3) sitting, 
(item 4) speech disturbance, (item 5) finger chase, (item 6) 
nose-finger test, (item 7) fast alternating hand movements, 
and (item 8) heel-shin slide [21]. We generated three 
composite subscores by taking the average scores o f the 
subsets of SARA items. Averaging the scores o f SARA 
items 1, 2, and 8 generated a lower body ataxia composite 
subscore that ranges from 0 (no ataxia) to 6 (most severe 
ataxia). An upper body composite subscore consisted of
*£) Springer
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Table 1 Homozygous or 
compound heterozygous muta­
tions in SACS gene
a Non-Dutch patients
Family Consanguinity Mutations Type of mutation
1 Yes p.Gln4054X/p.Gln4054X Nonsense
2 Yes p.Arg728X/p.Arg728X Nonsense
3 No p.Lys1715X/p.Arg4331Gln Nonsense/Missense
4 No p.Gln4054X/p.Arg2002fs Nonsense/Frameshift
5a Yes p.Glu1653X/p.Glu1653X Nonsense
6 No p.Gln4054X/c.2094-2 A>G Nonsense/Splice-site
7 Yes p.Asp168Tyr/p.Asp168Tyr Missense
8 No p.Gln4054X/p.Gln4054X Nonsense
9 Yes p.2801delGln/p.2801delGln In frame deletion
10 Not known p.Gln4054X/p.Gln4054X Nonsense
11 No c.1891+1 del G/c.1891+1 del G Splice-site
12 Not known p.Gln1709X/p.Gln4054X Nonsense
13 No p. Arg321X/p. Arg3636X Nonsense
14 No p.Gln4054X/p.Gln4054X Nonsense
15 No p.Arg321X/p.Trp492X Nonsense/Nonsense
16a No p.Leu3304fs/p.Leu3481Pro Frameshift/Missense
items 5, 6, and 7. The maximum scores on composite 
subscores may range from 0 (no ataxia) to 4 (severe ataxia). 
A “remaining” ataxia composite subscore consisted of 
items 3 and 4 that range from 0 (no ataxia) to 5 (worst). 
Finally, to fully characterize patients and compare the three 
composites, we normalized these subscores to percentages 
o f  the maximum score. Lower body spasticity was 
separately and semi-quantitatively rated according to the 
INAS (Inventory o f Non-Ataxia Symptoms) as, none, mild, 
moderate, or severe [21]. Furthermore, the ataxia disease 
stages were defined as: 0 = normal; 1 = ataxia, but walking 
independently; 2 = permanently dependent on walking aids;
3 = permanently dependent on wheelchair; and 4 = death 
[22]. If  possible, clinical records o f previous neurological 
consultations were reviewed to obtain data on the disease 
progression.
Results
Mutation analysis
In 16 out of 43 index patients, mutations in the SACS gene 
were identified. In six families, the mutations could be 
confirmed in seven additional affected siblings or relatives. 
We thus identified mutations in 23 patients. Molecular 
genetic analysis revealed nine index patients with homozy­
gous mutations and seven index patients with compound 
heterozygous mutations (Table 1). In total, 16 different 
novel mutations were identified: eight nonsense, three 
missense, two splice-site, one in frame deletion, and two 
frame-shift mutations (Table 1). The mutations occurred 
throughout the whole gene without any hot-spot regions 
(Fig. 1). All mutations most likely lead to a loss o f function. 
For the in frame deletion (p.2801delGln) in family 9, the
prediction programs are inconclusive. Whether this muta­
tion indeed leads to a loss o f function is unknown. 
However, the p.2801delGln mutation segregated with the 
disease in the family was not identified in 100 control 
alleles, and the mutation is located in a conserved region of 
the gene. In general, a 3-bp deletion is considered to have a 
larger deleterious effect on the protein function than a 
m issense m utation. A ll three patients carrying the 
p.2801delGln display a relatively severe phenotype, as all 
were wheelchair-bound before the age o f 15. In family 3, 
the identified heterozygous m issense m utation  (p. 
Arg4331Gln) is located in the highly conserved DnaJ 
domain in exon 6 o f the SACS gene. This mutation is 
predicted to be intolerant (PolyPhen—www.genetics.bwh. 
harvard.edu/pph/— and SIFT—www.blocks.fhcrc.org/sift/ 
SIFT.html) and probably leads to loss o f function o f the 
protein. The mutation (c. 2094-2 A>G) in family 6 
presumably induces skipping o f exon 5 due to loss o f the 
splice-acceptor site (www.fruitfly.org/cgi-bin/seq_tools/ 
splice.htlml, www.cbs.dtu.dk/services/NetGene2/, www. 
genet.sickkids.on.ca/~ali/splicesitefinder.html). Skipping of 
exon 5 most likely leads to absence of sacsin protein. The 
transcript lacking exon 5 is likely subject to nonsense­
m ediated m essenger RNA decay (NMD) due to a 
downstream protein truncating codon (PTC) occurring as 
a result o f a shift o f the reading frame. The splice site 
mutation (c.1891+1 del G) in family 11 affects the splice- 
donor site, either leading to a downstream PTC and 
subsequent NMD or to skipping o f exon 5. The identified 
homozygous missense mutation (p.Asp168Tyr) in family 7 
is considered to be pathogenic because the amino acid 
chance is predicted to be intolerant (PolyPhen and SIFT), 
the change is located in a conserved region, and was not 
identified in 100 control alleles. The same mutation was 
also identified in another affected relative o f whom both
Ô  Springer
Table 2 Phenotypic characteristics o f  patients w ith A R SA C S
Family Patient Age at Disease
duration
Disease
31
Gait
spasticity
Lower body 
ataxia score
Lower
limb
Upper body 
ataxia score
Upper
limb
Remaining
ataxia
SARA
total
Tendon reflexes Additional Sensomotor
axonal
Cerebellar vermis atrophy 
MRI/CT (disease duration(M /F ) onset stage
Ankle
symptoms
(years) (years) (% ) spasticity (%) spasticity score (%) score UL Knee neuropathy in years)
(0 ^ 0 ) (EMG)
1 1(M) 3 36 2 + + + 61.1 + + + 25.0 - 30 17 n h a dysphagia, urinary 
dysf.
nd Moderate (29)
2 2(F) 3 42 3 + + + 83.3 + + + 37.5 - 20 21.5 n h a +, D Severe (35)
3 3(M) 8 45 3 + + + 88.9 + + + 33.3 - 10 21 a n a Urinary dysf. +, D Severe (27)
4 4 (F f 3 33 3 + + + 94.4 + + + 33.3 - 20 23 n n a Urinary dysf. + Severe (24)
5 5(M)b 5 32 2 n a a nd
6 6(F) 1 39 3 + + + 86.1 + + 50.0 - 20 23.5 n h a Urinary dysf. + Moderate (34)
7 7(M)
8(F)
1
3
33
28
3
3
+++ 86.1 ++ 41.7 20 22.5 n h
h
a
h
nd
nd
Moderate (24) 
Moderate (23)
8 9(M) 1 26 2 + + + 66.7 + + + 37.5 + 30 19.5 n h a Cystic kidney 
right, dystonic 
posturing UL
+, D Mild (17)
9 10(F) 2 27 3 +++ 100 +++ 33.3 - 10 23 n n a Urinary dysf. + Moderate (18)
11(F) 1 25 3 +++ 100 +++ 41.7 40 27 h h a Urinary dysf., 
dystonia UL
nd nk
12(M) 1 25 3 +++ 63.9 ++ 41.7 + 30 19.5 n n a Dystonia neck + 
UL, dysphagia
+ Mild (12)
10 13(F) 2 29 2 +++ 44.4 ++ 33.3 20 14 n h a Urinary
dysfunction
+ nk
14(F) 3 31 2 + + 38.9 + 45.8 - 40 16.5 a a a Dysphagia +, D nk
11 15(M) 12 39 3 na 100 +++ 58.3 + 70 28 a a a Dysphagia, urinary 
dysf.
nd Severe (30)
16(M) 6 41 2 ++ 61.1 ++ 37.5 10 16.5 a n a impairment,
diabetes,
dysphagia
nd Severe (38)
12 17(F)
18(F)
13 19(M)a 2 56 3 na 100 ++ 54.2 + 70 31.5 a a a dysphagia, urinary 
dysf.
+,D Severe (38)
20(M) 1 56 3 na 100 na 54.2 na 60 30.5 a a a Dysphagia, urinary 
dysf. cognitive 
impairment
+, D Severe (48)
14 2 1(M) <10 26 + - Steatosis hepatis
15 22(F) 3 53 3 + + 1 n a Urinary
dysfunction
+, D Severe (53)
16 23(M)b 9 40 nk + + Nk nk b a nk + nk
+ m ild, ++ m oderate, +++ severe, n norm al, h hyperreflexia, a areflexia, -  none, nk  no t know n, D  secondary dem yelinating, n d  not done, na no t able to assess 
a baclofen pum p, b N on-D utch patients
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Fig. 1 Overview o f different 
mutations in the SACS gene. M  
missense, N  founder, N  non­
sense, A  deletion, F  frameshift, 
Ss splice site
M Na N M F  A F N N N  S s N S s N  N M
h nnnn  
ÏT T T T
DnaJ
□
HEPN
reverse strand 
NM_014363.4
parents were also consanguineous within the same extended 
family. The mutation most likely leads to a conformation 
change o f the protein resulting in dysfunction o f the 
protein. The missense mutation identified in family 16 
(English descent) is most likely pathogenic because it 
concerns a drastic change o f an evolutionary highly 
conserved amino acid; however, we are still waiting for 
DNA to confirm the mutation in the affected sibling. The 
nonsense mutation p.Gln3907X, identified in 7 out o f 14 
unrelated Dutch ARSACS patients is a common Dutch 
nonsense mutation.
Clinical data
Twenty-one patients from 14 different families with 
homozygous or compound heterozygous mutations in the 
SAC S  gene were o f Dutch descent. Family 5 originated 
from Turkey and family 16 is from English descent. All 
patients identified were adults, but onset o f gait impairment 
in the 21 patients o f whom clinical data were available was 
before age 13 (mean 3.7 years, SD 3.1, range 1-12). The 
mean disease duration in these 21 patients was 36.2 years 
(SD 9.9, range 25-56). Clinically, all identified patients 
carrying SACS mutations showed a remarkable uniform 
phenotype: mild to moderate ataxia o f the upper half o f the 
body with a severe spastic paresis, with sensory and motor 
neuropathy o f the lower limbs and very mild motor 
neuropathy of the upper limbs, and with cerebellar atrophy 
on neuroimaging (Table 2). This phenotype is consistent 
with the core ARSACS phenotype previously described.
Atthe time ofthe clinical examination, the majority (n =13) 
o f the patients were permanently wheelchair-dependent. The 
current clinical details in combination with older medical 
records suggest that the initial years o f disease were 
dominated by a slowly progressive cerebellar ataxia with 
subsequent lower limb spasticity, followed by features of 
peripheral neuropathy. This ultimately led to an impressive 
and severe lower limb and gait impairment, while oculomo­
tor disturbances, dysarthria, and upper limb ataxia appeared 
to progress much slower. The sensorimotor peripheral 
neuropathy was evident from distal muscle atrophy and
weakness, foot deformities, impaired tactile and vibration 
sense, and eventually a decrease or loss of tendon reflexes in 
the legs. Slight dysphagia and urinary dysfunction (predom­
inantly urge incontinence) were fairly common. Three 
patients (no. 9, no. 11, and no. 12) displayed subtle yet 
unequivocal abnormal posturing o f the hands and/or neck, 
indicative o f mild dystonia in these patients; other extrapy­
ramidal features were absent. Two patients (no. 4 and no. 20) 
used an intrathecal Baclofen pump, which influences the 
outcome of the SARA score on lower limb function. In our 
Dutch ARSACS cohort, no patient was mentally retarded nor 
showed signs o f dementia. Only two patients displayed mild 
cognitive problems. One of these (no. 15), had suffered from 
meningitis at age 44 and developed diabetes at age 56. He 
had experienced a recent episode o f epileptic seizures. The 
other patient (no. 20) had suffered from strokes. In 15 
patients who had undergone a brain magnetic resonance 
imaging (MRI) or computed tomography (CT) scan, moder­
ate to severe mid-cerebellar (vermis) atrophy was noticed, 
the severity o f which appeared to parallel disease duration. In 
12 patients, an electrocardiogram (ECG) was made and 
echocardiography was performed. One patient (no. 1) 
showed a right bundle branch block on ECG; no other 
ECG abnormalities were seen either in this patient or in any 
other. None of the examined patients displayed signs of 
mitral valve prolapse or any other cardiac abnormalities on 
echocardiography. On ophthalmologic examination, all 14 
patients that were examined showed demarcation o f the 
retinal nerve fibers that embedded parts o f the vessels near 
the disc (Fig. 2). In one patient (no. 7), a papilla leparina 
could be seen. In patients no. 19 and no. 20, no 
ophthalmologic examination and cardiologic examination 
was done, and no cardiologic examination could be 
performed in patient no. 6 due to limited mobility.
Discussion
In this report, we demonstrate that in the Dutch population, 
mutations in the SACS  gene are quite prevalent among 
patients with early-onset cerebellar ataxia. Moreover, those
Ö  Springer
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Fig. 2 Red-free fundus photograph of patient no. 12; increased 
demarcation o f the retinal nerve fibers, partially embedded retinal 
vessels; and a distinct tortuosity o f the retinal vessels near the optic 
disc are seen
who harbored mutations in the SACS gene showed a strikingly 
uniform and recognizable clinical phenotype consisting of 
cerebellar ataxia with onset before the age of 13, lower limb 
spasticity and sensorimotor axonal neuropathy, and cerebellar 
(vermis) atrophy on neuroimaging.
Originally believed to be a rare disease that was present 
in Quebec only, ARSACS turns out to constitute a fairly 
common phenotype in the diverse group o f early-onset 
recessive cerebellar ataxias. We identified many different 
novel mutations throughout the whole gene. The clinical 
phenotype is specific and recognizable, thus offering a 
good indication for mutation analysis. In this study, the 
detection rate o f ARSACS mutations in the SACS gene 
among 43 patients with an early-onset recessive cerebellar 
ataxia was 37%. Retrospectively, we can conclude that all 
identified ARSACS patients displayed mild to moderate 
upper body ataxia and severe spastic paresis o f the lower 
limbs with neuropathy. In two patients with more or less 
similar neurological features, no mutations in the SACS 
gene could be identified. This might be due to genetic 
heterogeneity for the spastic ataxia phenotype. The 
principle o f genetic heterogeneity for the spastic ataxia 
phenotype is demonstrated by reports o f patients with 
spastic ataxia who harbor mutations in the FRDA gene 
and o f patients who are linked to the SPG30, SAX2, and 
ARSAL loci [23- 28].
Furthermore, in retrospect, these two patients had less 
lower limb spasticity compared to the ARSACS patients 
and, contrary to these, prominent atrophy and weakness of 
the intrinsic hand muscles. On the other hand, we cannot 
exclude that mutations in both SACS alleles might have 
remained undetected, for instance when they reside in parts 
o f the gene that have not been analyzed, e.g., regulatory 
regions upstream o f the gene or deep in the introns. The
average age o f onset o f the disease in our cohort is 
comparable to what has been described in literature, except 
for one Tunisian case in whom the age o f onset was 
20 years [29].
Mitral valve prolapse has been mentioned as a frequent 
feature among ARSACS patients from Quebec [4]. After 
the publication of Bouchard et al. [4], cardiac involvement 
in ARSACS patients has not been further reported. This is 
consistent with the absence o f cardiac symptoms in patients 
from our cohort. Therefore, we conclude that cardiac 
involvement is not a clinical characteristic o f ARSACS. 
Increased demarcation of the retinal fibers embedding parts 
of the vessels near the disc has previously been reported as 
being a common feature o f ARSACS among patients 
originating from Quebec and o f some other ARSACS 
patients [4 , 8, 9, 13, 15, 30, 31]. Eight of the 14 patients 
whom we ophthalmologically examined not only did show 
increased demarcation o f the retinal nerve fibers but also 
had a distinct tortuosity o f the retinal vessels near the optic 
disc (Fig. 2).
Our data demonstrate that mental retardation, defined as 
having an IQ of less than 70, is not a feature o f ARSACS. 
So far, only two ARSACS patients described in the 
literature fulfill this criterion. However, as their spastic- 
ataxic sibs were not mentally retarded, the retardation is 
most likely an independent feature not related to ARSACS 
[13, 17]. In three patients, mild dystonic features were 
observed. Dystonia has not been reported in other ARSACS 
patients, but extrapyrimadal features such as dystonia and 
chorea are known to occur in Friedreich’s ataxia, ataxia 
telangiectasia, ataxia with oculomotor apraxia type 1, and 
ataxia with vitamin E [32- 35]. So far, only two adult 
ARSACS patients (with mutations in the SACS gene) 
without lower limb spasticity have been reported. The 
absence o f this feature was suggested to be due to the 
severe progressive neuropathy that could mask spasticity 
[9, 18]. Assuming a uniform clinical ARSACS phenotype 
and given the still labor-intensive procedure o f fully 
sequencing this large gene, it seems currently advisable to 
screen the SACS gene only in those patients who present 
with early-onset slowly progressive cerebellar ataxia, with 
lower limb spasticity and peripheral neuropathy, with 
relatively mild oculomotor disturbances and upper limb 
ataxia, and in whom Friedreich’s ataxia has been excluded.
In conclusion, 16 novel SACS mutations were identified 
in 16 different families consisting o f 23 patients in whom 
the clinical phenotype was very similar and consistent with 
the core ARSACS phenotype, mild to moderate upper body 
ataxia and severe spastic paresis o f the lower limbs and 
neuropathy, with cerebellar atrophy revealed by neuro­
imaging. The identification of several different mutations in 
the SACS gene in this first mutational screen in Dutch 
patients with an early-onset cerebellar ataxia indicates that
Springer
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ARSACS is more prevalent in the Dutch population than 
previously assumed. This could also be the case in other 
populations.
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